心肌纤维化在心力衰竭中的演变作用与保存的喷射分数
Muhammad K Malik1,2, Menhel Kinno3,4, Max Liebo3
1Department of Internal Medicine, Loyola University Medical Center, Maywood, IL, United States.
Frontiers in cardiovascular medicine
|May 8, 2025
概括
保持喷射分数 (HFpEF) 的心力衰竭涉及透支功能障碍和纤维化. 新型生物标志物对检测心肌间歇性纤维化 (MIF) 和改善患者预后有希望,可能减少对侵入性方法的需求.
科学领域:
- 心脏病学 心脏病学
- 病理生理学 病理生理学
- 生物标志物发现发现
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭具有复杂的,异质的临床特征.
- 扩张功能障碍,左心室重塑和心肌间歇性纤维化 (MIF) 是HFpEF的特征.
- MIF的结果是原沉积,受到心力衰竭的特定原因的影响.
研究的目的:
- 探索用于检测HFpEF患者MIF的新生物标志物.
- 调查这些生物标志物的预后价值.
- 评估生物标志物的潜力,以取代侵入性诊断方法.
主要方法:
- 对HFpEF病理生理学和MIF检测现有文献的综述.
- 对MIF的新兴生物标志物研究的调查.
- 分析新生物标志物的潜在临床应用.
主要成果:
- MIF是HFpEF的一个关键特征,与原沉积有关.
- 侵入性组织病理学和成像是目前用于MIF检测的方法.
- 新的生物标志物正在成为MIF检测和预测的潜在工具.
结论:
- 生物标志物为HFpEF中MIF评估提供了一个有希望的,不那么侵入性的替代方案.
- 对生物标志物的进一步研究可以提高患者的预后和治疗策略.
- 生物标志物的发展可能会减少对HFpEF管理的侵入性程序的依赖.
更多相关视频
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
27.7K
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.3K
相关概念视频
Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
316
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
316
Pathophysiology of Cardiac Performance
488
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
488
Heart Failure Drugs: Diuretics
291
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
291
